Fomivirsen

Fomivirsen
Clinical data
AHFS/Drugs.com Micromedex Detailed Consumer Information
Intravitreal injection
Identifiers
160369-77-7 Yes
S01AD08
KEGG D02736 Yes
ChEMBL CHEMBL1201688 
Chemical data
Formula C204H263N63O114P20S20
6682.4 g/mol
  (what is this?)  (verify)

Fomivirsen (brand name Vitravene) is an antiviral drug. It is used in the treatment of cytomegalovirus retinitis (CMV) in immunocompromised patients, including those with AIDS. It was licenced by the FDA for CMV in Aug 1998.

It is a synthetic 21 member oligonucleotide with phosphorothioate linkages (which are resistant to degradation by nucleases) and has the sequence:

Mechanism

It is an oligonucleotide[1] that blocks translation of viral mRNA by binding to the complementary sequence of the mRNA transcribed from the coding segment of a key CMV gene. It was the first antisense antiviral approved by the FDA.[2]

Administration

It is available as an intraocular injection in a concentration of 6.6 mg/mL.[3]

See also

References

  1. ↑ Mulamba GB, Hu A, Azad RF, Anderson KP, Coen DM (April 1998). "Human Cytomegalovirus Mutant with Sequence-Dependent Resistance to the Phosphorothioate Oligonucleotide Fomivirsen (ISIS 2922)". Antimicrob. Agents Chemother. 42 (4): 971–3. PMC 105584. PMID 9559825.
  2. ↑ Roush W (May 1997). "Antisense aims for a renaissance". Science 276 (5316): 1192–3. doi:10.1126/science.276.5316.1192. PMID 9182327.
  3. ↑ Katzung, Bertram G. (2006). Basic and Clinical Pharmacology (10th ed.). New York: McGraw-Hill Medical Publishing Division. p. 817. ISBN 0-07-145153-6.

Further reading

  • Grillone, LR; Lanz, R (2001). "Fomivirsen". Drugs Today (Barc) 37 (4): 245–255. PMID 12768225.
  • Geary R, Henry S, Grillone L (2002). "Fomivirsen: clinical pharmacology and potential drug interactions". Clin Pharmacokinet 41 (4): 255–60. doi:10.2165/00003088-200241040-00002. PMID 11978144.
  • Vitravene Study, Group (2002). "Randomized dose-comparison studies of intravitreous fomivirsen for treatment of cytomegalovirus retinitis that has reactivated or is persistently active despite other therapies in patients with AIDS". Am J Ophthalmol 133 (4): 475–83. doi:10.1016/S0002-9394(02)01326-0. PMID 11931781.
  • Roehr B (1998). "Fomivirsen approved for CMV retinitis". J Int Assoc Physicians AIDS Care 4 (10): 14–6. PMID 11365956.

External links